Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

R. Bramhall, Simon; S. Rosemurgy, Alexander; de Nully Brown, Peter; Bowry, C.; Buckels, J.A.C.; the Marimastat Pancreatic Cancer Study Group, for

doi:10.1200/jco.2001.19.15.3447

Public

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

Published in Journal of Clinical Oncology • Aug 1, 2001

Authors:

Simon R. Bramhall

Alexander S. Rosemurgy

Peter de Nully Brown

Abstract

PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer per...

Subject

Gemcitabine

Medicine

Pancreatic cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!